you need patience my friend
No link added
Micron: AI Memory Supercycle Is Now Showing Up In Revenue, Margins And Cash Flow
Micron is starting to show clear signs that growing demand from AI data centers is lifting sales, profit, and cash coming in the door, not just future promise. The big question now is whether it can keep this momentum going long enough to justify how much optimism is already baked into the stock.Read more
Robinhood Markets will skyrocket with 25% revenue growth
Recent news: As of April 2026, the SEC approved a FINRA proposal to eliminate the Pattern Day Trader (PDT) rule, removing the requirement for a minimum balance to make more than three day trades in a five-day period. Instead of a flat equity requirement, new risk-based margin standards will require traders to maintain sufficient equity for their real-time exposure.Read more
Hermès - Expensive bags, and expensive stock. And the story of €14 billion of bearer shares gone missing.
About Hermès International SA Hermès International SA is a French luxury goods manufacturer. Its core business is leather goods.Read more
Coca-Cola’s Enduring Moat in a Health-Conscious World: Steady Compounder Poised for 5-10% Annual Returns Through Emerging Market Dominance
Business Model in Simple Terms Imagine Coca-Cola as the world’s most powerful “thirst quencher” franchise. The company doesn’t bottle most of its drinks—it sells concentrated syrup and branding rights to independent bottlers worldwide.Read more
The "Physical AI" Monopoly – A New Industrial Revolution
Tesla ($TSLA) has officially exited the automotive peer group. By dismantling legacy Model S/X lines to build humanoid robots, the company has declared its transition from a car manufacturer to the world’s first "Physical AI" platform.Read more
Looking to be second time lucky with a game-changing new product
Unicycive’s kidney drug aims to make life easier for dialysis patients by cutting down the daily pill burden, and it could finally reach the market after a manufacturing setback. The next big moment is the regulator’s decision, but the same manufacturing and rollout risks still hang over the story.Read more
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
Roche is lining up a new wave of potential hit medicines across obesity, cancer, and multiple sclerosis, with many important trial results expected soon. The big question is whether these programs succeed before tougher competition and upcoming patent expiries start to bite.Read more
Insiders Sell, Investors Watch: What’s Going On at PG?
Over the last year, the share price of Procter & Gamble (PG:NYSE) has fallen from around $175 to roughly $140, with most of the decline occurring since March. This weakness may partly reflect layoffs announced earlier in the year amid tariff-related uncertainty, and the stock may now be drifting into oversold territory.Read more
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Eli Lilly’s growth hinges on surging demand for its diabetes and weight-loss medicines, with supply expansion and better insurance coverage helping more patients access them. The big question is whether high prices, side effects, and new rivals can slow momentum before Lilly’s manufacturing catch-up pays off.Read more
